Gynecologic Oncology

Patient Care Lead by Distinguished Physician-Scientists

Named as a National Center of Excellence in Women's Health, University of Minnesota Health's Gynecologic Cancer Care program is at the forefront of gnecologic cancer treatments and therapies. A diagnosis of gynecologic cancer can impact many areas of a woman's life, affecting each woman and her family differently. M Health's integrated team of cancer specialists works diligently to meet the individual needs of patients by providing clear information, emotional support, and expert medical advice. Our physician-scientists have dedicated their lives to continually investigating new cancer prevention and treatment options which means our patients receive cutting-edge expertise, and state-of-the-art care. If you've been diagnosed with a gynecologic cancer, we understand you'll be facing some challenging decisions during your cancer journey. You can rest-assured that we will be by your side every step of the way providing personalized, proactive and patient-driven care.

Minneapolis

Minneapolis

MINNEAPOLIS

Cancer Clinic (Masonic Cancer Clinic)                                                          
University of Minnesota Health - Clinics & Surgery Center
Floor 2
909 Fulton St. SE
Minneapolis, MN 55455
Appointments: 855-486-7226
Provider Referrals: 855‑486‑7226  
Information: 612‑273‑8383
 

Burnsville

Burnsville

BURNSVILLE

Ridges Cancer Clinic, University of Minnesota Medical Center 
Suite 200
​14101 Fairview Dr.
Burnsville, MN 55337
Appointments: 952‑460‑4074
Provider Referrals: 855‑486‑7226
Information: 952‑460‑4074

Maple Grove

Maple Grove

MAPLE GROVE

Gynecologic Cancer
University of Minnesota Health
Lower Level
​14500 99th Ave. N
Maple Grove 55369
Appointments: 763‑898‑1600
Provider Referrals: 855‑486‑7226
Information: 763‑898‑1600

St. Louis Park

St. Louis Park

ST. LOUIS PARK

Gynecologic Cancer
​6500 Excelsior Blvd. 
St. Louis Park, MN 
Appointments: 952-993-3282
Provider Referrals: 952-993-0330

St. Paul

St. Paul

ST. PAUL

Gynecologic Cancer
640 Jackson St.
St. Paul, MN 55101
Appointments: 651-254-3572

Ovarian Cancer

Ovarian Cancer

Ovarian Cancer (includes fallopian tube and primary peritoneal cancer)      
Protocol Number - link to MHealth Short Title Primary Study Goal (Can further simplify if needeed) Contact Information
2016CG020 Phase III of Olaparib in recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer Assess efficacy of either single agent olaparib or combination of cediranib and olaparib compared to the standard platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian, primary peritioneal, or fallopian tube cancer Study Contact: Kimbery Brunsvold
Phone: 612-626-2315
Email: kwren@umn.edu

PI: Melissa Geller, MD
2016CG029 (Currently on hold for review) Phase II/III of Cediranib and Olaparib in ovarian, fallopian tube or peritoneal cancer (COCOS) Assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy in patients with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. Study Contact: Kimbery Brunsvold
Phone: 612-626-2315
Email: kwren@umn.edu

PI: Melissa Geller, MD
2015IS019 QUADRA: P2 l Niraparib in Ovarian, Fallopian and Peritoneal CA after 3 Prior Treatments To evaluate the antitumor activity of niraparib. Patients enrolled must have already undergone 3 or 4 prior treatments Study Contact: Kimbery Brunsvold
Phone: 612-626-2315
Email: kwren@umn.edu

PI: Melissa Geller, MD
2014IS121 Phase 2 of Farletuzumab (MORAb-003) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Demonstrate that farletuzumab has superior efficacy compared with placebo in improving progression-free survival (PFS) as determined by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 when added to one of two standard chemotherapy regimens (carboplatin plus paclitaxel or carboplatin plus PLD) in subjects with ovarian cancer in first platinum-sensitive relapse who have a CA125 ≤ 3x ULN at study entry. Study Contact: Kimbery Brunsvold
Phone: 612-626-2315
Email: kwren@umn.edu

PI: Melissa Geller, MD
2016NTLS163 Development Of A Clinical Precision Medicine Program In Ovarian Cancer As A Paradigm For 21st Century Tailored-Health Care Solutions - Conduct a pilot study to determine feasibility of a robust Clinical Precision Medicine Program for women with ovarian cancer
- To prospectively identify and classify ovarian tumors into molecular subtypes
Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Boris Winterhoff, MD
2016NTLS151
Cytomegalovirus and Adaptive Natural Killer Cells in Ovarian Cancer: A Pilot Study
- To compare rates of CMV in patients diagnosed with advanced-stage ovarian, primary peritoneal, or fallopian tube cancer to age-matched controls (women undergoing surgery for benign indications).
- To compare NK cell functionality between women with advanced-stage ovarian, primary peritoneal, or fallopian tube cancer and age-matched controls.
Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Melissa Geller, MD
       
2014NTLS003 Gene Expression in Epithelial Ovarian Cancer Tumors after NACT To compare levels of gene expression in epithelial ovarian cancer tumors before and after the administration of Neo-Adjuvant Chemotherapy (NACT). Evaluate for association between different gene expression in epithelial ovarian cancer tumors and development of platinum resistance. Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Tim Starr, Ph.D
2014NTLS069 AVATAR: Personalized mouse models of chemotherapy resistance in ovarian cancer Primary: Conduct a pilot study to determine feasibility of PDX models for response to first line chemotherapy in ovarian cancer.
Sub-aim A: Establish PDX models.
Sub-aim B: Determine response to chemotherapy of PDX models.
Sub-aim C: Identify gene expression patterns in PDX models.
Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Tim Starr, Ph.D
2016NTLS071 Risk Factors of 'Chemo Brain' among Women Treated for Ovarian Cancer Examine association between characteristics such as age, education, co-morbidities, and therapy delivery compared to cognitive decline (or "Chemo Brain") following Chemotherapy. Evalute how genetic variation in APOE4 influences vulnerability to "Chemo Brain." Determine if low levels of vitamin B12 in the blood is associated with "Chemo Brain" Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Rachel Isaksson Vogel, Ph.D
2014NTLS004 MAGIC: Mobile Application for Genetic Information on Cancer    
2011NTLS157 Use of Pap test samples to study human diseases To identify molecular and cellular differences between woment with diseases such as gynecologic cancer and healthy control women using Pap Tests and vaginal swabs. Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Amy Skubitz, Ph.D
2006NT001 Biomarker with Biological Function in Ovarian Carcinoma Validate that the ten cell adhesion proteins, corresponding to the ten known genes that we have found to be specifically unregulated in ovarian carcinoma, are present in ovarian carcinoma tissues. Determine the association between protein expression and the pathology of the samples, including patient information. Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Amy Skubitz, Ph.D
       
       
       
     

Endometrial Cancer

Endometrial Cancer

Endometrial Cancer
     
Protocol Number  Short Title Primary Study Goal  Contact Information
2015CG028 GOG-0286B P1/2 Paclitaxel/Carbo/Metformin VS Pac/Carbo/Placebo in Endometrial CA - Determine if the addition of metformin to the standard regimen of
carboplatin and paclitaxel prolongs progression-free survival (PFS) in
women with advanced or recurrent endometrial cancer (Phase II).
- To determine if the addition of metformin to the standard regimen of
carboplatin and paclitaxel prolongs overall survival (OS) in the same
population if a phase III study is conducted.
Study Contact: Kimbery Brunsvold
Phone: 612-626-2315
Email: kwren@umn.edu

PI: Melissa Geller, MD
2016NTLS130 T cells in genitourinary tumors (Endometrial) - Characterize resident memory T-Cells (immune cells) derived from human tumors and activate these T-cells in the lab using peptide stimulation.
- Delineate virus-specific T-cell populations in tumors compared to bloods
- T-Cell receptor sequencing of tumor infiltrating lymphocytes to assess clonality
Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: David Masopust, Ph.D

Cervical Cancer

Cervical Cancer

Cervical Cancer
     
Protocol Number  Short Title Primary Study Goal  Contact Information
2015CG177 Phase 3 of ADXS11-001 in Locally Advanced Cervical Cancer: AIM2CERV To compare the progression free survival (PFS) rate of ADXS11-001 to placebo administered in the adjuvant setting following concurrent chemotherapy and radiotherapy (CCRT) administered with curative intent to subjects with high-risk locally advanced squamous, adenosquamous, or adenocarcinoma of the cervix (HRLACC). Study Contact: Aaron Grad
Phone: 612-626-2960; 507-398-7610
Email: gradx005@umn.edu

PI: Britt Erickson, MD

Uterine Cancer

Uterine Cancer

Vulvar Cancer

Vulvar Cancer

Vaginal Cancer

Vaginal Cancer

Fallopian (Tubal) Cancer

Fallopian (Tubal) Cancer